Urigen Pharmaceuticals, Inc. News
Urigen Pharmaceuticals Retains Redington for Investor Programs
BURLINGAME, Calif.,
"Redington has been retained to expand Urigen's outreach and visibility in the US financial community, with particular emphasis on transactional brokers, wealth managers and high net worth individuals," said Martin Shmagin, Urigen CFO. "As Urigen's clinical programs develop, this outreach program will be expanded to include sector growth investment funds."
Among the companies Redington has helped with investment community sponsorship are Amgen, Calgene, Elan, Celgene, Keryx, Medarex and Crucell.
"Urigen is in the process of building out its drug portfolio and moving forward on the strength of clinical achievements," noted
With specific expertise in the biopharma industry, Redington will assist Urigen in developing and managing investor relations programs that will include market road shows and investor meetings in principal financial centers across America.
About Urigen
Urigen Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen's product development programs target significant unmet medical needs and major market opportunities in urology. URG101 targets painful bladder syndrome/interstitial cystitis, which affects approximately 10.5 million men and women in
About Redington
Redington, Inc. is a financial communications and investor relations firm with a specialty practice for emerging life sciences companies. It provides a full range of communications and corporate services, including message development, presentation structure and content, market road shows, editorial products including executive speeches, news releases, investor literature and annual reports, media relations, institutional and analyst introductions, and broker relationship management. For more information please visit www.redingtoninc.com.
Contact: Martin E. Shmagin Chief Financial Officer 650-259-0239 www.urigen.com Thomas Redington 203/222-7399 212/926-1733 www.redingtoninc.com
SOURCE Urigen Pharmaceuticals, Inc.
Search Our News Using Google Search
Can't find what you want? Try using Google:
